These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28374590)

  • 1. Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis.
    Mallipeddi S; Kreimer S; Zvonok N; Vemuri K; Karger BL; Ivanov AR; Makriyannis A
    J Proteome Res; 2017 Jul; 16(7):2419-2428. PubMed ID: 28374590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.
    Szymanski DW; Papanastasiou M; Melchior K; Zvonok N; Mercier RW; Janero DR; Thakur GA; Cha S; Wu B; Karger B; Makriyannis A
    J Proteome Res; 2011 Oct; 10(10):4789-98. PubMed ID: 21861534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.
    Zhou H; Peng Y; Halikhedkar A; Fan P; Janero DR; Thakur GA; Mercier RW; Sun X; Ma X; Makriyannis A
    ACS Chem Neurosci; 2017 Jun; 8(6):1338-1347. PubMed ID: 28220706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.
    Mercier RW; Pei Y; Pandarinathan L; Janero DR; Zhang J; Makriyannis A
    Chem Biol; 2010 Oct; 17(10):1132-42. PubMed ID: 21035736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
    Janero DR; Korde A; Makriyannis A
    Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.
    Alqarni M; Myint KZ; Tong Q; Yang P; Bartlow P; Wang L; Feng R; Xie XQ
    Biochem Biophys Res Commun; 2014 Sep; 452(3):334-9. PubMed ID: 25148941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
    Pandey P; Roy KK; Doerksen RJ
    J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.
    Pei Y; Mercier RW; Anday JK; Thakur GA; Zvonok AM; Hurst D; Reggio PH; Janero DR; Makriyannis A
    Chem Biol; 2008 Nov; 15(11):1207-19. PubMed ID: 19022181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor.
    Zvonok N; Yaddanapudi S; Williams J; Dai S; Dong K; Rejtar T; Karger BL; Makriyannis A
    J Proteome Res; 2007 Jun; 6(6):2068-79. PubMed ID: 17472360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
    Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
    Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system.
    Filppula S; Yaddanapudi S; Mercier R; Xu W; Pavlopoulos S; Makriyannis A
    J Pept Res; 2004 Dec; 64(6):225-36. PubMed ID: 15613086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.
    Zhang Y; Xie Z; Wang L; Schreiter B; Lazo JS; Gertsch J; Xie XQ
    Int Immunopharmacol; 2011 Sep; 11(9):1303-10. PubMed ID: 21539938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins.
    Szymanski D; Papanastasiou M; Pandarinathan L; Zvonok N; Janero DR; Pavlopoulos S; Vouros P; Makriyannis A
    J Med Chem; 2018 Dec; 61(24):11199-11208. PubMed ID: 30444608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
    Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of G protein-coupled receptor-Gi protein interaction: formation of the cannabinoid CB2 receptor-Gi protein complex.
    Mnpotra JS; Qiao Z; Cai J; Lynch DL; Grossfield A; Leioatts N; Hurst DP; Pitman MC; Song ZH; Reggio PH
    J Biol Chem; 2014 Jul; 289(29):20259-72. PubMed ID: 24855641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.
    Latek D; Kolinski M; Ghoshdastider U; Debinski A; Bombolewski R; Plazinska A; Jozwiak K; Filipek S
    J Mol Model; 2011 Sep; 17(9):2353-66. PubMed ID: 21365223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryo-EM Structure of the Human Cannabinoid Receptor CB2-G
    Xing C; Zhuang Y; Xu TH; Feng Z; Zhou XE; Chen M; Wang L; Meng X; Xue Y; Wang J; Liu H; McGuire TF; Zhao G; Melcher K; Zhang C; Xu HE; Xie XQ
    Cell; 2020 Feb; 180(4):645-654.e13. PubMed ID: 32004460
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Gianquinto E; Sodano F; Rolando B; Kostrzewa M; Allarà M; Mahmoud AM; Kumar P; Spyrakis F; Ligresti A; Chegaev K
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.
    Hu J; Feng Z; Ma S; Zhang Y; Tong Q; Alqarni MH; Gou X; Xie XQ
    J Chem Inf Model; 2016 Jun; 56(6):1152-63. PubMed ID: 27186994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.
    Gianella-Borradori M; Christou I; Bataille CJ; Cross RL; Wynne GM; Greaves DR; Russell AJ
    Bioorg Med Chem; 2015 Jan; 23(1):241-63. PubMed ID: 25487422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.